[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 509
Citations 0
News From the Food and Drug Administration
December 1, 2015

New Pancreatic Cancer Drug

JAMA. 2015;314(21):2227. doi:10.1001/jama.2015.16166

Irinotecan liposome injection, marketed as Onivyde, has been approved in combination with fluorouracil and leucovorin to treat patients with metastatic pancreatic cancer who previously received gemcitabine-based chemotherapy.

In a study including 417 patients with metastatic pancreatic cancer that progressed after treatment with gemcitabine, those who took irinotecan with fluorouracil and leucovorin lived an average of 6.1 months compared with 4.2 months for those treated only with fluorouracil and leucovorin (http://1.usa.gov/1kvFKVt).

First Page Preview View Large
First page PDF preview
First page PDF preview
×